Table 1 Patient Data.

From: Inhibition of epileptiform activity by neuropeptide Y in brain tissue from drug-resistant temporal lobe epilepsy patients

Patient

Resistance to >2 AEDs

Age at surgery (yrs)

Duration of epilepsy (from onset; yrs)

Seizure frequency (n/mo)

AEDs at surgery

Hippocampal pathology

1

yes

31

12

1 (SFS)

1 (CFS)

LTG, LEV

HS

2

yes

57

5

9 (CFS)

OXC

HS

3

yes

34

8

3 (CFS)

CBZ, LEV, LAC

HS

4

yes

19

13

6 (SFS)

6 (CFS)

LEV, CBZ

HS

5

yes

23

22

4 (CFS)

LEV, LAC

HS

6

yes

27

8

25 approx.

LAM, FRI,

VAL

Neuronal loss

and gliosis

7

yes

44

7

5 (CFS)

LTG, ZNS, BRI

Normal

8

yes

24

10

20 (CFS)

LAC

HS

9

yes

42

6

2 (CFS)

CLB, LAC, ZNS

HS

10

yes

38

35

5 (CFS)

FEN, LTG, LEV, LAC

HS

  1. Seizure frequency reported by patients in Copenhagen (CPH) as simple focal seizures (SFSs) and complex focal seizures (CFSs). Abbreviations are as follows: carbamazepine Brivaracetam (BV), (CBZ), clobazam (CLB), Fenytoin (FEN) hippocampal sclerosis (HS), lacosamide (LAC), levetiracetam (LEV), lamotrigine (LTG), oxcarbazepine (OXC), valproate (VPA) and zonesamide (ZNS).